I posted this on the Kazia board, but it is equally relevant here. Harvett had implied that Non-Final Rejections were the kiss-of-death for Noxopharm's patent applications
With respect, Harvett, I think you need to do some homework.
The USPTO shows Novogen as the assignee for 29 granted Patents. I checked 18 of these before realising that further checks were unnecessary, because EVERY granted patent had initially been rejected by the Examiner. In those 18 applications, there were 30 Non-Final Rejections; 8 Final Rejections; 3 successful Appeals; and in the end 18 out of 18 Patents were allowed. I expect the other 11 were the same
NO Novogen patents went through the system without a Non-Final Rejection. NONE.
A patent application is like an ambit wage claim for 10% which the union would be happy to settle for 5%. Patent attorneys never expect to get every claim granted, but they give it their best shot. Non-Final and even Final Rejections are expected, and even anticipated when formulating an application (so that the applicant can drop some claims as a compromise?).
It is important that investors know how this system works. There is no need to panic if a Non-Final Rejection is issued.
NOX Price at posting:
37.5¢ Sentiment: None Disclosure: Held
